The technique of RT-qPCR (real time-quantitative polymerase chain reaction) is invaluable in miRNA research both at the profi ling and individual RT-qPCR stages. At the profi ling stage, numerous miRNAs are looked at in the plasma of numerous individuals from two or more cohorts ( i.e ., control vs. case). The miR-NAs of interest would be either upregulated or downregulated by more than twofold in the case cohort compared to the control cohort. Profi ling human specimens for miRNA biomarkers has exploded over the last decade, with researchers profi ling plasma, serum, urine, and also the miRNA content of extracellular vesicles, which are also isolated from human specimens. RT-qPCR is a relatively easy technique; however, sample preparation from plasma to RNA to RNA input in RT reaction requires accuracy and precision.
Introduction
Metabolic syndrome (MetS) is the culmination of a number of components, i.e ., hypertension, dyslipidemia, abdominal obesity and insulin resistance, resulting in an increased risk of type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD) , and cancer [ 1 ] . Obesity is reaching epidemic proportions world-wide and therefore; the rate of MetS is steadily increasing alongside obesity. There is call for a novel method for diagnosis of MetS to subsequently reduce the risk of T2DM, CVD and cancer, which are among the leading causes of death globally [ 1 ] . microRNAs (miRNA) are small, approximately 22 nucleotide long noncoding RNA molecules found in animals, plants, and numerous viruses. miRNAs regulate gene expression via their association with target sites on mRNAs and association with effector complexes [ 2 ] . Their function is posttranscriptional gene regulation, primarily downregulation of the target protein through translational repression (binding or cleavage) of the target mRNA untranslated regions. However, recent studies have shown miRNAs can function to posttranscriptionally stimulate gene expression, by working in concert with their associated proteins, microribonucleoproteins by a direct or indirect mechanism [ 2 ] . It is therefore, not surprising that aberrant miRNA expression is associated with numerous disorders, including obesity [ 3 , 4 ] , diabetes [ 4 ] , and various cancer subtypes [ 5 , 6 ] .
In recent years, miRNA profi ling has developed as the preferred method over traditional gene expression profi ling due to (1) the stability of miRNAs, this is due to their short length, (2) high sensitivity, (3) reliable as diagnostic tools, and (4) the origin of cancer at a metastatic site can be determined [ 5 ] . Additionally, miRNAs are easily assessed in body fl uids, i.e. , serum and plasma; therefore, they are minimally invasive biomarkers. However, they can also be assessed in tumor or tissue specimens. In this method plasma miR-NAs from obese individuals and individuals diagnosed with MetS according to the International Diabetes Federation were analyzed.
Numerous high-throughput miRNA profi ling technologies exist, including, Quantitative reverse Transcription PCR (RT-qPCR), miRNA microarray , and RNA sequencing, either smaller scale or high-throughput [ 5 ] . In this chapter we discuss the use of the miR-CURY LNA™ Universal RT miRNA qPCR Panels. This method was selected as (1) the RT reaction is universal and so supplies templates for all miRNAs in the qPCR reaction and (2) both the reverse and forward amplifi cation primers are specifi c to the miRNA of interest providing notable sensitivity and specifi city.
Blood plasma is a pale yellow liquid and acts as the extracellular matrix of blood cells. It accounts for 55 % of the body's total blood volume. In this method, plasma was chosen for further miRNA analysis as the preparation of plasma is less complex than that for serum . Preparation of plasma involves centrifugation of whole blood to remove white blood cells and red blood cells; however, serum requires blood clotting followed by centrifugation. Plasma isolated from EDTA tubes was, therefore, used to reduce the procedural variation resulting from differences in clotting and subsequent serum collection.
Materials
1. TRI Reagent ™, should be used in the fume hood: store at 4 °C.
2. Chloroform, should be used in the fume hood: store at 4 °C.
3. 120 μg/mL of glycogen: store at −20 °C for up to 1 year. 4. Isopropanol: store at 4 °C.
5.
Ethanol: prepare 75 % using ddH 2 O and store at room temperature.
6. RNase-free water: store at room temperature.
RNA Isolation and Quality Control

Methods
RNA from plasma is isolated using TRI Reagent ™ and the resulting RNA is quantifi ed using the NanoDrop . Care is needed when isolating RNA, as RNase enzymes easily degrade RNA. Therefore, benches should be wiped with RNaseZap and 70 % ethanol. Eppendorfs and RT-qPCR plates should be RNase-free, RNase-free fi lter tips should be used and all reagents should be molecular grade.
1. Plasma specimens are procured by standard collection protocols. Specifi cally, whole blood is procured in EDTA vials and mixed by inversion of the tube (8-10 times). Specimens are immediately centrifuged at 2000 × g at room temperature (RT) for 15 min. Following centrifugation the top yellowish layer is collected and stored in 1 mL aliquots in cryovials at −80 °C until required.
2. Plasma specimens are thawed slowly on ice, 250 μL is transferred to an Eppendorf and plasma specimens are returned to −80 °C. 250 μL of plasma and 750 μL of TRI Reagent ™ ( see Note 2 ) are combined, mixed, and incubated at RT for 10 min.
3. To this, 200 μL of chloroform is added, mixed vigorously for 15 s and incubated at RT for 10 min.
4. After incubation the resulting mixture is centrifuged at 13,200 × g at 4 °C for 15 min to separate the RNA, DNA, and protein layers. 8. The supernatant is discarded and the pellet is washed with 75 % ethanol and vortexed. The pellet is then centrifuged at 7500 × g at 4 °C for 5 min.
Agilent
9.
Step 8 is repeated, however, centrifuged at 13,200 × g .
10. The RNA pellet is then allowed to air dry until translucent and resuspended in 10 μL of RNase-free water. The resuspended RNA pellet is incubated on ice for 30 min to allow complete dissolution.
11. Store RNA at −80 °C ( see Notes 3 and 4 ).
12. Quantifi cation of the RNA is performed using the NanoDrop , with readings taken at 260, 280 and 230 nm ( see Notes 2 and 3 ).
1. Agilent small RNA chips are used to assess the quality and percentage of miRNAs present in the total RNA sample.
2. The chip is placed on the priming station and 9 μL of gel matrix with dye concentrate is added to the appropriate well ( Fig. 1a ).
Quality Assessment: Agilent Chips ( See Notes 4 and 5 )
1 4. The plunger is released and moved to the 1 mL mark.
5.
The priming station is opened and 9 μL of gel matrix is added to two additional wells (Fig. 1b ).
6. 9 μL of conditioning solution is added to the appropriate well ( Fig. 1c ) .
7. To all sample wells and the ladder well, 5 μL of marker is added (Fig. 1d ).
8. Finally, 1 µL of denatured RNA sample is added to wells numbered 1-11 ( Fig. 1e ).
9. To the ladder well, 1 µL of ladder solution is added (Fig. 1f ).
10. The chip is then placed in the IKA vortex for 1 min at 2400 rpm.
11. Subsequently the chip is placed in the BioAnalyzer ( see Notes 4 and 5 ) and results visualized on an electropherogram (Fig. 2 ).
There are many techniques available for miRNA profi ling as is described in the introduction. Here, we will provide the protocol for the use of miRCURY LNA™ Universal RT miRNA qPCR panels for use with serum /plasma. Under this category of miRNA profi ling there are a number of options available to the researcher, i.e ., miRNome panels, focus panels and pick and mix custom panels. The basic principal of the RT-qPCR is the same for all options; the choice of panel depends on the researchers focus.
Although quantifi cation of the RNA is performed using the NanoDrop , the amount of RNA present in a plasma specimen cannot be accurately determined due to phenol contamination from the TRI Reagent ™. Therefore, an input volume of RNA rather than an input concentration is the preferred option. Performing a serial dilution of RNA input volumes will determine the correct 4. Place solution in a trough and using a multichannel pipette 10 μL into each well of the 384-well plates.
MicroRNA Profi ling (Discovery Phase)
5.
Seal the plate and centrifuge for 1 min at 1200 × g to bring contents to bottom of well ( see Note 8 ).
6. Place plate in real-time PCR machine and run the following cycle:
(a) Hold Stage -95 °C for 10 min.
(b) PCR Stage (×40 cycles).
• 95 °C for 10 s. miRNAs identifi ed as upregulated or downregulated from the miRNA profi ling need to be validated in a separate cohort of specimens. The method involves the synthesis of cDNA and qPCR analysis similar to the miRNA profi ling, discovery phase.
First strand cDNA synthesis is performed as per Subheading 3.3.1 (Fig. 3 ). Following calibration miRNA profi ling data is analyzed using the 2 (−ΔΔC T ) method. Specifi cally:
1. ΔC T = C T value of sample − C T value (mean C T value) of endogenous control gene(s). 
ΔΔC
Data Analysis
A.
B.
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Step 1: Reverse Transcription
Step 2: PCR SYBR Green Labelled Amplified cDNA Step 1 A: a poly-A tail is added to the mature miRNA.
Step 1 B: cDNA is synthesized using a poly-T primer with a 5′ universal tag.
Step 2 A: The cDNA template is then amplifi ed using forward and reverse primers.
Step 2 B: SYBR Green is used for detection of the amplifi ed cDNA 4 Notes 1. RNA spike-ins , such as UniSp6 may be used in the RT reaction and PCR stages to ensure the RT reaction was successful and undetermined values in the PCR are not due to poorly synthesized cDNA.
2. When isolating using TRI Reagent ™ or TRIzol contamination with phenol may result. Therefore, NanoDrop readings may be inaccurate and RNA input volume may be superior to input concentration in the RT reaction.
3. RNA input volume should be determined by serial dilution, in order to ensure there are no RT reaction inhibitors in the plasma specimens.
4. Isolated RNA should be stored at −80 °C no longer than 30 min after reconstitution in order to ensure integrity of RNA for subsequent RT reaction.
5. Plasma RNA will not show the 18S rRNA or 28S rRNA when using the Agilent Pico kit. Plasma will also only show the miRNA content when using the Agilent Small RNA kit. 6 . Use of Agilent BioAnalyzer should be restricted to areas where other instruments are not being used, as vibrations from other instruments may skew results.
7. Setting up of RT and PCR reactions should be done extremely carefully to avoid as much as possible pipetting error.
8. Premade PCR reaction plates may be stored for 24 h at 4 °C.
